--- title: "KLOW Peptide: What's in It, Evidence and Legal Status" description: "KLOW is a blend of KPV, BPC-157, TB-500 and GHK-Cu. No human trial has tested the combination. Evidence per ingredient, US status as of Oct 17, 2026, and…" canonical: https://plainlygraded.com/stacks/klow/ last_updated: 2026-10-17 breadcrumb: "Home > Stacks and blends > KLOW" publisher: Plainly Graded policy: "No dosing, no sourcing, no vendor links. Every claim cites a public source." --- > We collect and compare information from public, cited sources. We cannot guarantee that it is complete, current or correct. This is not medical advice. Only a doctor can prescribe, and a doctor should confirm anything you read here before you act on it. # KLOW Four-peptide blend: KPV, BPC-157, TB-500 and GHK-Cu. Also sold as "KLOW blend", "KLOW stack" - FDA: not approved - WADA: contains 2 prohibited substances - No human trial of the blend STATUS AS OF 17 OCT 2026 **KPV ·** FDA: not FDA-approved for any use · 503A: not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed · WADA: not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use · [tracker entry](https://plainlygraded.com/regulatory/#kpv) **BPC-157 ·** FDA: not FDA-approved for any use · 503A: not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed · WADA: prohibited at all times under the 2026 WADA List (S0, non-approved substances) · [tracker entry](https://plainlygraded.com/regulatory/#bpc-157) **TB-500 ·** FDA: not FDA-approved for any use · 503A: not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed · WADA: prohibited at all times under the 2026 WADA List (S2.3: thymosin beta-4 and its derivatives, e.g. TB-500) · [tracker entry](https://plainlygraded.com/regulatory/#tb-500) **GHK-Cu ·** FDA: legal as a cosmetic ingredient; not FDA-approved as a drug · 503A: injectable form off Category 2 since April 15, 2026 but not eligible for compounding; FDA advisers are due to review it before the end of February 2027 · WADA: not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use · [tracker entry](https://plainlygraded.com/regulatory/#ghk-cu) **The short answer:** KLOW is an unapproved four-peptide blend of KPV, BPC-157, TB-500 and GHK-Cu, and as of October 17, 2026 no human trial has tested the combination. Each ingredient has been studied mostly in cells and animals. None is an FDA-approved drug, and two of the four are banned in sport at all times. Written by [Maren Holt](https://plainlygraded.com/about/team/) 17 PUBLIC SOURCES · UPDATED 17 OCT 2026 · NO TIES TO SELLERS [How we source](https://plainlygraded.com/how-we-source/) ### KLOW at a glance: evidence grade by ingredient | Ingredient | What it is | Grade | FDA | WADA 2026 | | --- | --- | --- | --- | --- | | [KPV](https://plainlygraded.com/peptides/kpv/) | Three-amino-acid fragment of the hormone alpha-MSH | **Evidence grade D** | Not approved | Not named · ask USADA | | [BPC-157](https://plainlygraded.com/peptides/bpc-157/) | Synthetic 15-amino-acid fragment of a gastric protein | **Evidence grade C** | Not approved | S0 prohibited | | [TB-500](https://plainlygraded.com/peptides/tb-500/) | Synthetic fragment of thymosin beta-4, a repair-related protein | **Evidence grade D** | Not approved | S2 prohibited | | [GHK-Cu](https://plainlygraded.com/peptides/ghk-cu/) | Copper-binding three-amino-acid peptide found in human blood | **Evidence grade C** | Not approved as a drug | Not named · ask USADA | | **KLOW (the blend)** | No published human or animal study of the combination | **Evidence grade U** | Not approved | Prohibited | A blend is graded as a blend: good evidence for an ingredient does not transfer to the mix. [How we grade](https://plainlygraded.com/evidence-grading/) ## What is in KLOW? KLOW is a blend of four peptides sold together in one vial: KPV, BPC-157, TB-500 and GHK-Cu. The name comes from the first letters, with the "K" from KPV added to an older three-peptide mix called GLOW. Sellers market KLOW for recovery, skin, gut health and inflammation. People search for it under names like "KLOW blend", "KLOW stack" and "KLOW 80". The last of these is a seller's product label, not a different compound. **Note:** We don't list amounts. Sellers mix these four peptides in different proportions and often don't publish them. Any breakdown you see online describes one seller's label, not a standard formula, and we have not seen independent testing that confirms what those labels say. [Why we don't publish doses or ratios](https://plainlygraded.com/why-we-dont-give-dosing/) ## Why are these four peptides combined? The case for KLOW is a theory about complementary effects. Each ingredient has been linked, mostly in animal and cell studies, to a different part of tissue repair or inflammation. The combination itself has never been tested. - BPC-157 has been studied in rodents for tendon, muscle and gut healing, and for blood-vessel growth. - TB-500 is a fragment of thymosin beta-4. The full protein plays a role in cell movement and wound repair. - GHK-Cu has been studied for collagen production and skin repair, mostly as a cream. - KPV has been studied in mice and in gut cells for calming inflammation, especially in models of colitis. The theory says that four mechanisms add up. That is a reasonable hypothesis, but a hypothesis about a blend is not evidence for it. Peptides mixed together can behave differently from peptides studied alone, and no published study of KLOW has checked whether they do. ## What does the evidence show for each KLOW ingredient? BPC-157. The largest recent review screened 544 papers. Of the 36 that met its criteria, 35 were in rodents or cells, and only one involved people. In the US, one clinician has published three very small human reports: 12 people with knee pain, 12 with a bladder condition called interstitial cystitis, and a two-person intravenous check. None had a comparison group. A company ran a mid-stage trial of BPC-157 for ulcerative colitis years ago, but its results have never been published. TB-500. Most of the human evidence people cite for TB-500 was gathered on full-length thymosin beta-4, tested as eye drops for corneal and dry-eye conditions. TB-500 is a short synthetic fragment of that protein, and a result for the eye-drop product does not transfer to an injected fragment. GHK-Cu. As a skin cream, copper peptide has decades of small human studies on wrinkles and skin firmness, many funded by the cosmetics industry. NPR reported in September 2026 that "there is no data from published human studies to show this practice is safe and effective" for injecting it. KPV. KPV reduced signs of colitis in mouse studies and calmed inflammatory signalling in human gut cells grown in the lab. We found no published human trial of KPV for any condition. ## Has KLOW itself been tested in people? No. As of October 17, 2026, we found no published human trial, animal study or registered clinical trial that tested KLOW, or any blend of these four peptides, as a combination. We searched PubMed and ClinicalTrials.gov on that date. - Interactions are unknown. Nobody has measured whether the four peptides change each other's effects or side effects. - Stability is unknown. Nobody has published data on whether the four stay intact when stored mixed together. - Reports can't be traced to an ingredient. If someone feels better or worse on KLOW, there is no way to tell which ingredient, if any, was responsible. ## What are the side effects and risks of KLOW? KLOW's side effects have not been studied, because the blend has never been tested in a trial. What is known comes from the separate ingredients, from reports on injected products in general, and from regulators. - Injection problems. People who inject unregulated products report redness, swelling and pain where they inject, and there is a risk of infection if the product or process isn't sterile. - Contamination and wrong contents. In July 2026, FDA staff told the agency's advisers they had concerns about impurities, bacterial toxins and unreliable certificates for several of these peptides. - Immune reactions. FDA staff also flagged that nobody knows how often these peptides trigger an immune response. - Copper load. GHK-Cu carries copper. Clinicians have reported raised copper and liver-enzyme levels in some people who injected it, though the cause wasn't established. - Theoretical cancer concern. BPC-157 and thymosin beta-4 have been linked in lab studies to new blood-vessel growth, which tumors also rely on. No study has shown either causes or worsens cancer in people, and none has ruled it out. ## Is KLOW legal in the US, and is it banned in sport? KLOW is not an FDA-approved drug, and as of October 17, 2026 no pharmacy can lawfully compound it. None of its four ingredients is approved by the FDA as a drug. On July 23, 2026, a majority of FDA's compounding advisers voted in favor of adding KPV, BPC-157 and TB-500 to the list pharmacies can compound from. The vote is advice, not a rule, and FDA has not proposed a rule. Injectable GHK-Cu was taken off Category 2 on April 15, 2026 but not cleared for compounding. On October 7, 2026, The Washington Post reported that the administration is drafting a temporary policy to let some compounding pharmacies supply certain restricted peptides. As of October 17, no policy has been published, and the report did not name which peptides. In sport, WADA's 2026 Prohibited List bans BPC-157 (section S0) and TB-500 (section S2) at all times. Because KLOW contains both, the blend is prohibited. KPV and GHK-Cu are not named on the list; ask USADA before using either. ## KLOW vs GLOW: what's the difference? GLOW is BPC-157, TB-500 and GHK-Cu. KLOW is the same three plus KPV. The added KPV is sold for gut and inflammation claims, and like the other three it has no published human trial. Neither blend has been tested as a combination, and both contain two substances banned in sport. ### What sellers claim vs what has been shown | Claimed | Shown | | --- | --- | | Speeds healing of tendons and muscles | In rodents, for BPC-157 and thymosin beta-4. Not shown in controlled human trials, and not tested for the blend.[1,8] | | Reduces gut inflammation | In mice and gut cells, for KPV and BPC-157. No human trial.[6] | | Improves skin | Small human studies of copper peptide creams. Not shown for injected GHK-Cu or for KLOW.[7,16] | | "Tested and pure" (certificate of analysis) | Certificates are often produced by labs tied to the seller. They are not an FDA quality check.[9] | What we don't know - Whether the four peptides interact: no study of the combination exists. - Whether they stay stable when mixed: no published stability data. - What is actually in products sold online: there is no required quality testing. - Effects in pregnancy: there is no human data on any ingredient. Why this page has no dosing We don't publish doses, schedules or mixing instructions for KLOW or any unapproved peptide. No human dose has been established for most of these uses, so we list what to ask a licensed prescriber instead. [Here's why, and who can legally answer](https://plainlygraded.com/why-we-dont-give-dosing/) Get medical help now if you have - Swelling of the face, lips or throat, trouble breathing, chest pain, a racing heart or fainting. **Call 911.** - Redness spreading from an injection site, warmth, pus or a fever. Get same-day care. - Unsure what you took or whether a reaction is serious: **Poison Control 1-800-222-1222** (free, 24 hours). - Thoughts of harming yourself: call or text **988**. Who should be especially careful - **If you are pregnant, trying to get pregnant or breastfeeding.** There is no human data on any of these ingredients in pregnancy. - **If you have or have had cancer.** Because of the theoretical blood-vessel growth concern, talk with your oncology team first. - **If you compete in tested sport or serve in the military.** KLOW contains two substances prohibited at all times. - **If you are under 18.** None of these peptides has been studied in young people. - **If you have liver disease or a copper-related condition such as Wilson disease.** GHK-Cu adds copper. ### Compare next - [KPV](https://plainlygraded.com/peptides/kpv/) - [BPC-157](https://plainlygraded.com/peptides/bpc-157/) - [TB-500](https://plainlygraded.com/peptides/tb-500/) - [GHK-Cu](https://plainlygraded.com/peptides/ghk-cu/) - [GLOW](https://plainlygraded.com/stacks/glow/) - [Wolverine stack](https://plainlygraded.com/stacks/wolverine-stack/) **Sources** 1. HSS Journal. [Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review](https://pubmed.ncbi.nlm.nih.gov/40756949/), 2025. PMID 40756949. 2. Alternative Therapies in Health and Medicine. [Intra-articular injection of BPC 157 for multiple types of knee pain](https://pubmed.ncbi.nlm.nih.gov/34324435/), 2021. PMID 34324435. 3. Alternative Therapies in Health and Medicine. [BPC 157 for interstitial cystitis: a pilot study](https://pubmed.ncbi.nlm.nih.gov/39325560/), 2024. PMID 39325560. 4. Alternative Therapies in Health and Medicine. [Safety of intravenous BPC 157 in adults: a pilot study](https://pubmed.ncbi.nlm.nih.gov/40131143/), 2025. PMID 40131143. 5. ClinicalTrials.gov. [BPC-157 in ulcerative colitis (trial record)](https://clinicaltrials.gov/study/NCT02637284). NCT02637284. 6. Inflammatory Bowel Diseases. [Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease](https://pubmed.ncbi.nlm.nih.gov/18092346/), 2008. PMID 18092346. 7. International Journal of Molecular Sciences. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data, 2018. 8. ClinicalTrials.gov. Thymosin beta-4 (RGN-259) eye-drop trials in neurotrophic keratopathy and dry eye. 9. US Food and Drug Administration. Pharmacy Compounding Advisory Committee, meeting of July 23-24, 2026: briefing documents and vote record, 2026-07-23. 10. US Food and Drug Administration. 503A bulk drug substances: interim categories, updated April 15, 2026, 2026-04-15. 11. US Food and Drug Administration. Warning letters to five online peptide sellers, August 24, 2026, 2026-08-24. 12. World Anti-Doping Agency. [2026 Prohibited List (sections S0 and S2)](https://www.wada-ama.org/en/prohibited-list), 2026-01-01. 13. Operation Supplement Safety (US Department of Defense). [BPC-157](https://www.opss.org/node/512764). 14. DLA Piper. [FDA AdComm recommends adding six peptides to bulk list](https://www.dlapiper.com/en-ae/insights/publications/2026/07/fda-adcomm-recommends-adding-six-peptides-to-bulk-list), 2026-07-31. (law-firm or secondary summary) 15. McDermott Will & Emery. [Bulk list bound? PCAC backs majority of peptides in two-day public meeting](https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/), 2026-07-27. (law-firm or secondary summary) 16. NPR. [The copper peptide trend has gone from creams to injections, ahead of the science](https://www.kuow.org/npr-news/2026-09-07/the-copper-peptide-trend-has-gone-from-creams-to-injections-ahead-of-the-science), 2026-09-07. (news report) 17. Becker's Hospital Review. [HHS plans stopgap to allow sales of some unapproved peptides: Washington Post](https://www.beckershospitalreview.com/glp-1s/hhs-plans-stopgap-to-allow-sales-of-some-unapproved-peptides-washington-post/), 2026-10-08. (news report) **Changelog** 17 OCT 2026 Draft 1.0. Statuses checked against the regulatory record dated 2026-10-17. Spotted an error? [Report it](https://plainlygraded.com/corrections/). We never change a page's updated date without changing its content. --- We collect and compare information from public, cited sources. We cannot guarantee that it is complete, current or correct. This is not medical advice. Only a doctor can prescribe, and a doctor should confirm anything you read here before you act on it. Canonical page: https://plainlygraded.com/stacks/klow/